Matti Mauramo1,2, Luzius Rohde3, Adrian M Ramseier3, Alicia Rovó4, Tuomas Waltimo3. 1. Institute of Preventive Dentistry and Oral Microbiology, School of Dental Medicine, University of Basel, Basel, Switzerland. matti.mauramo@helsinki.fi. 2. Institute of Dentistry, Scientific Research Laboratory, Biomedicum, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, FI-00014, Helsinki, Finland. matti.mauramo@helsinki.fi. 3. Institute of Preventive Dentistry and Oral Microbiology, School of Dental Medicine, University of Basel, Basel, Switzerland. 4. Department of Haematology, University Hospital Basel, Basel, Switzerland.
Abstract
OBJECTIVES: The aetiology of hyposalivation in haematopoietic stem cell transplantation (HSCT) recipients is not fully understood. This study examined the effects of treatment-related aetiological factors, particularly medications, on stimulated salivary flow in HSCT recipients. SUBJECTS AND METHODS: Adult HSCT recipients (N = 118, 66 males, 27 autologous and 91 allogeneic transplants) were examined. Stimulated whole salivary flow rates (SWSFR) were measured before HSCT and at 6 and 12 months post-HSCT. Linear regression models were used to analyse the associations of medications and transplant-related factors with salivary flow rates, which were compared to salivary flow rates of generally healthy controls (N = 247). RESULTS: The SWSFR of recipients were lower pre-HSCT (mean ± standard deviation, 0.88 ± 0.56 ml/min; P < 0.001), 6 months post-HSCT (0.84 ± 0.61; P < 0.001) and 12 months post-HSCT (1.08 ± 0.67; P = 0.005) than the SWSFR of controls (1.31 ± 0.65). In addition, hyposalivation (<0.7 ml/min) was more frequent among HSCT recipients pre-HSCT (P < 0.001), 6 months post-HSCT (P < 0.001) and 12 months post-HSCT (P = 0.01) than among controls. The SWSFR was observed to improve over time being significantly higher 12 months post-HSCT compared to pre-HSCT (P < 0.001). The observed decrease of salivary flow could not be explained by the examined transplant-related factors and medications. CONCLUSIONS: Decreased stimulated salivary flow rates could not be explained by the examined factors alone; these findings indicate that hyposalivation in HSCT recipients exhibits a multifactorial aetiology. CLINICAL RELEVANCE: All HSCT recipients should be considered to be at high risk of hyposalivation and consequent oral diseases, and they should be treated accordingly.
OBJECTIVES: The aetiology of hyposalivation in haematopoietic stem cell transplantation (HSCT) recipients is not fully understood. This study examined the effects of treatment-related aetiological factors, particularly medications, on stimulated salivary flow in HSCT recipients. SUBJECTS AND METHODS: Adult HSCT recipients (N = 118, 66 males, 27 autologous and 91 allogeneic transplants) were examined. Stimulated whole salivary flow rates (SWSFR) were measured before HSCT and at 6 and 12 months post-HSCT. Linear regression models were used to analyse the associations of medications and transplant-related factors with salivary flow rates, which were compared to salivary flow rates of generally healthy controls (N = 247). RESULTS: The SWSFR of recipients were lower pre-HSCT (mean ± standard deviation, 0.88 ± 0.56 ml/min; P < 0.001), 6 months post-HSCT (0.84 ± 0.61; P < 0.001) and 12 months post-HSCT (1.08 ± 0.67; P = 0.005) than the SWSFR of controls (1.31 ± 0.65). In addition, hyposalivation (<0.7 ml/min) was more frequent among HSCT recipients pre-HSCT (P < 0.001), 6 months post-HSCT (P < 0.001) and 12 months post-HSCT (P = 0.01) than among controls. The SWSFR was observed to improve over time being significantly higher 12 months post-HSCT compared to pre-HSCT (P < 0.001). The observed decrease of salivary flow could not be explained by the examined transplant-related factors and medications. CONCLUSIONS: Decreased stimulated salivary flow rates could not be explained by the examined factors alone; these findings indicate that hyposalivation in HSCT recipients exhibits a multifactorial aetiology. CLINICAL RELEVANCE: All HSCT recipients should be considered to be at high risk of hyposalivation and consequent oral diseases, and they should be treated accordingly.
Authors: Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: Smita Bhatia; Liton Francisco; Andrea Carter; Can-Lan Sun; K Scott Baker; James G Gurney; Philip B McGlave; Auayporn Nademanee; Margaret O'Donnell; Norma K C Ramsay; Leslie L Robison; David Snyder; Anthony Stein; Stephen J Forman; Daniel J Weisdorf Journal: Blood Date: 2007-08-01 Impact factor: 22.113
Authors: M Laaksonen; A M Ramseier; A Rovó; S B Jensen; J E Raber-Durlacher; N U Zitzmann; T Waltimo Journal: J Dent Res Date: 2011-07-06 Impact factor: 6.116
Authors: T Daikeler; M Mauramo; A Rovó; M Stern; J Halter; A Buser; A Tyndall; P Häusermann; A Gratwohl; A Tichelli; M T Brennan; T Waltimo Journal: Bone Marrow Transplant Date: 2013-01-07 Impact factor: 5.483
Authors: L M Bezinelli; F P Eduardo; D L C de Carvalho; C E Dos Santos Ferreira; E V de Almeida; L R Sanches; I Esteves; P V Campregher; N Hamerschlak; L Corrêa Journal: Bone Marrow Transplant Date: 2017-07-24 Impact factor: 5.483
Authors: Matti Mauramo; Patricia Grolimund; Adrian Egli; Jakob Passweg; Jörg Halter; Tuomas Waltimo Journal: PLoS One Date: 2019-12-18 Impact factor: 3.240